Nationwide
A Phase 1/2 Trial of VX-522 in People with Cystic Fibrosis
Vertex Pharmaceuticals Incorporated
Ph 1/2·~4yr·24 sites in AL, CA, CO +15
Vertex Pharmaceuticals Incorporated
Spirovant Sciences, Inc.
ReCode Therapeutics
Krystal Biotech, Inc.
University of Kansas Medical Center
Vertex Pharmaceuticals Incorporated
Arkansas Children's Hospital Research Institute
University of Cincinnati
SpliSense Ltd.
Chris Goss
University of Washington, the Collaborative Health Studies Coordinating Center
Johns Hopkins University
Vertex Pharmaceuticals Incorporated
Sionna Therapeutics Inc.
Indiana University
Milton S. Hershey Medical Center